Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $122.08.

AXSM has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, April 10th. Truist Financial restated a “buy” rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, March 26th. Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $108.00 to $112.00 and gave the company an “outperform” rating in a research report on Tuesday, May 7th. Mizuho restated a “buy” rating and issued a $106.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, June 12th. Finally, Citigroup reduced their target price on shares of Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $80.50 on Friday. The company has a 50-day moving average of $74.98 and a 200-day moving average of $78.68. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of -12.62 and a beta of 1.25. Axsome Therapeutics has a 52 week low of $55.02 and a 52 week high of $98.40. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.09 and a current ratio of 3.20.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.11. The company had revenue of $75.00 million during the quarter, compared to the consensus estimate of $69.91 million. Axsome Therapeutics had a negative net margin of 118.07% and a negative return on equity of 87.17%. As a group, equities research analysts anticipate that Axsome Therapeutics will post -4.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Mark L. Jacobson sold 24,662 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Mark L. Jacobson sold 24,662 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Mark L. Jacobson sold 7,910 shares of the stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total transaction of $587,792.10. Following the completion of the transaction, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $429,734.73. The disclosure for this sale can be found here. Insiders sold 37,821 shares of company stock valued at $2,887,462 over the last quarter. 22.40% of the stock is owned by company insiders.

Institutional Trading of Axsome Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. RTW Investments LP boosted its holdings in shares of Axsome Therapeutics by 4.8% during the 3rd quarter. RTW Investments LP now owns 4,489,596 shares of the company’s stock worth $313,778,000 after buying an additional 205,319 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Axsome Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock worth $298,474,000 after buying an additional 43,512 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Axsome Therapeutics by 115.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,038,019 shares of the company’s stock worth $82,616,000 after buying an additional 556,370 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Axsome Therapeutics by 57.4% during the 4th quarter. Point72 Asset Management L.P. now owns 837,201 shares of the company’s stock worth $66,633,000 after buying an additional 305,264 shares in the last quarter. Finally, Bellevue Group AG boosted its holdings in shares of Axsome Therapeutics by 7.9% during the 1st quarter. Bellevue Group AG now owns 685,476 shares of the company’s stock worth $54,701,000 after buying an additional 50,104 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.